How meningiomas change over time and new treatment targets
Project 2: Biological mechanisms and therapeutic vulnerabilities underlying meningioma evolution and heterogeneity
This project looks for molecular signs that predict which meningiomas will come back and finds drug targets to help people with aggressive or recurrent tumors.
Quick facts
| Grant type | P01 program project |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California, San Francisco NIH-funded |
| Lab location | 1 site (San Francisco, United States) |
| Project ID | NIH-11192771 on NIH RePORTER |
What this research studies
Researchers analyzed tumor samples from more than 2,000 meningiomas collected across many hospitals using DNA methylation, gene expression, and other molecular tests. They identified molecular groups and a gene expression marker that predict which tumors are more likely to recur and which may respond to radiotherapy or cell-cycle blocking drugs. This work aims to help doctors decide who needs extra treatment after surgery and to point to drugs that might work for aggressive tumors. The team is working to move these molecular tests into clinical guidelines and trials so patients can benefit from more personalized care.
Who could benefit from this research
Good fit: People with a diagnosis of meningioma—especially those having surgery, with recurrent tumors, or with WHO grade 2–3 disease—are the most likely candidates for tests or trials from this project.
Not a fit: People without meningioma, without available tumor tissue, or whose tumors are already well controlled may not see direct benefit from this work.
Why it matters
Potential benefit: Could allow more accurate prediction of tumor recurrence and direct patients to treatments more likely to work for their tumor.
How similar studies have performed: Other tumor profiling efforts have improved classification and treatment selection in brain tumors, and initial data from this project already show promise for predicting meningioma outcomes and therapy vulnerabilities.
Where this research is happening
San Francisco, United States
- University of California, San Francisco — San Francisco, United States (Active)
Researchers
- Principal investigator: Raleigh, David R — University of California, San Francisco
- Study coordinator: Raleigh, David R
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.